iopromide

Iopromide is a non-ionic, low-osmolar, monomeric iodinated contrast agent (ICA) developed by Schering AG (now Bayer) and marketed under the brand name Ultravist. It is used extensively in diagnostic imaging to enhance the visibility of blood vessels and organs during X-ray based procedures, including computed tomography (CT), digital subtraction angiography (DSA), and excretory urography. By absorbing X-ray radiation due to its high iodine content, iopromide provides the necessary contrast for the detection of neoplastic and non-neoplastic lesions, as well as the evaluation of cardiovascular and renal structures. It is available in various concentrations (e.g., 300 mgI/mL and 370 mgI/mL) to suit specific clinical requirements and is administered via intravenous or intra-arterial injection.

Brand names

Ultravist

Other names

IopromidumN,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide